Мальта - англійська - Malta Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - imatinib - film-coated tablet - imatinib 100 mg - antineoplastic agents

Мальта - англійська - Malta Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - lercanidipine hydrochloride - film coated tablet - 10 milligram - dihydropyridine derivatives

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - lercanidipine hydrochloride - film coated tablet - 20 milligram - dihydropyridine derivatives

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fingolimod hydrochloride, quantity: 560 microgram (equivalent: fingolimod, qty 500 microgram) - capsule, hard - excipient ingredients: iron oxide yellow; titanium dioxide; gelatin; sodium lauryl sulfate; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod-teva is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 2.5 milligram(s) - ace inhibitors, plain; ramipril

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 10 milligram(s) - ace inhibitors, plain; ramipril

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 5 milligram(s) - ace inhibitors, plain; ramipril

Європейський Союз - англійська - EMA (European Medicines Agency)

teva b.v. - telmisartan - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate; sucrose - azacitidine-teva is indicated for the treatment of patients with: intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukemia [cmmol (10 percent-29 percent marrow blasts without myeloproliferative disorder)], acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated